Table 2.
Clinical parameters, univariate and multivariate analyses of mccRCC patients treated by sunitinib and stratified by sPD-L1
| (a) Patient characteristics and univariate analysis with the Fisher or Ki2 test. Statistical significance (p values) is indicated | |||
|---|---|---|---|
| sPD-L1 ˂ 0.1 ng/ml | sPD-L1 ˃ 0.1 ng/ml | p value | |
| Number | 27 | 23 | |
| Age | 61.3 | 56 | ns |
| Sex | ns | ||
| Female | 6 (22.2%) | 4 (17.4%) | |
| Male | 21 (77.8%) | 19 (82.6%) | |
| pT | ns | ||
| 1/2 | 11 (45.8%) | 7 (30.4%) | |
| 3/4 | 13 (54.2%) | 16 (69.6%) | |
| x | 3 | 0 | |
| pN | ns | ||
| 0 | 24 (88.9%) | 19 (82.6%) | |
| ≥ 1 | 3 (11.1%) | 4 (17.4%) | |
| pM | ns | ||
| 0 | 18 (66.7%) | 12 (52.2%) | |
| 1 | 9 (33.3%) | 11 (47.8%) | |
| Stage | ns | ||
| I+ II | 8 (34.8%) | 4 (17.4%) | |
| III+IV | 15 (65.2%) | 19 (82.6%) | |
| x | 4 | 0 | |
| Fuhrman grade | ns | ||
| 1/2 | 11 (47.8%) | 5 (33.3%) | |
| 3/4 | 12 (52.2%) | 15 (66.7%) | |
| x | 4 | 3 | |
| PFS (months) | 22.5 | 11.3 | 0.008 |
| OS (months) | 47.3 | 28.5 | ns |
| (b) Multivariate analysis of sPD-L1, the stage score and PFS. The multivariate analysis was performed using Cox regression adjusted to the stage score. Statistical significance (p values) is indicated | |||
| HR | IC95% OR | P value | |
| sPD-L1 low vs high | 2.677 | [1.338–5.359] | 0.0053 |
| Stage I+ II vs III+IV | 1.465 | [0.673–3.19] | 0.3359 |